Astria Therapeutics (NASDAQ:ATXS) Trading Down 4.1%

Astria Therapeutics, Inc. (NASDAQ:ATXS)’s stock price was down 4.1% during mid-day trading on Wednesday . The company traded as low as $10.96 and last traded at $10.96. Approximately 4,053 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 678,856 shares. The stock had previously closed at $11.43.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ATXS. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Friday, September 27th. Wedbush reaffirmed an “outperform” rating and set a $22.00 price target on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Oppenheimer lifted their price objective on shares of Astria Therapeutics from $25.00 to $26.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 13th. TD Cowen assumed coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Astria Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $25.20.

Astria Therapeutics Stock Performance

The company’s fifty day moving average price is $11.31 and its 200-day moving average price is $10.75. The stock has a market cap of $641.93 million, a P/E ratio of -4.93 and a beta of 0.71.

Astria Therapeutics (NASDAQ:ATXS) last announced its earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Analysts anticipate that Astria Therapeutics, Inc. will post -1.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Astria Therapeutics

Hedge funds have recently bought and sold shares of the business. RA Capital Management L.P. purchased a new position in Astria Therapeutics in the 1st quarter worth about $62,115,000. Perceptive Advisors LLC grew its stake in Astria Therapeutics by 82.9% in the 4th quarter. Perceptive Advisors LLC now owns 4,004,070 shares of the biotechnology company’s stock worth $30,751,000 after acquiring an additional 1,814,608 shares in the last quarter. Vanguard Group Inc. grew its stake in Astria Therapeutics by 23.4% in the 1st quarter. Vanguard Group Inc. now owns 2,535,891 shares of the biotechnology company’s stock worth $35,693,000 after acquiring an additional 480,184 shares in the last quarter. Millennium Management LLC increased its position in shares of Astria Therapeutics by 13.5% during the second quarter. Millennium Management LLC now owns 1,842,063 shares of the biotechnology company’s stock worth $16,763,000 after acquiring an additional 218,518 shares during the period. Finally, Affinity Asset Advisors LLC raised its stake in shares of Astria Therapeutics by 15.4% during the second quarter. Affinity Asset Advisors LLC now owns 975,606 shares of the biotechnology company’s stock valued at $8,878,000 after acquiring an additional 130,000 shares in the last quarter. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.